BioCardia Shares Update from Japan PMDA Consultation on CardiAMP Autologous Cell Therapy for Ischemic Heart Failure; Foreign Data Expected to be Sufficient for Product Approval

December 15, 2023

https://www.globenewswire.com/news-release/2023/11/29/2787607/0/en/BioCardia-Shares-Update-from-Japan-PMDA-Consultation-on-CardiAMP-Autologous-Cell-Therapy-for-Ischemic-Heart-Failure-Foreign-Data-Expected-to-be-Sufficient-for-Product-Approval.html

SUNNYVALE, Calif., Nov. 29, 2023 (GLOBE NEWSWIRE) — BioCardia, Inc. [Nasdaq:BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today provided an update after its recent consultation with Japan’s Pharmaceutical and Medical Device Agency (PMDA) towards approval of its CardiAMP autologous cell therapy for the treatment of patients with ischemic heart failure of reduced ejection fraction (HFrEF).

Read more at globenewswire.com

Related news for (BCDA)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.